Abstract Library

#1348 Resectable Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Located to the Body or Tail and Unresectable Liver Metastases: Does Distal Pancreatectomy Improve Survival?

Introduction: The role of primary tumor surgery in pancreatic neuroendocrine tumor (PNET) with unresectable liver metastases is controversial and international guidelines do not recommend surgery in that setting of patients

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bertani E

Authors: Bertani E, Fazio N, Grana C, Chiappa A, Biffi R,

Keywords: PNET, surgery, liver metastases, distal pancreatectomy, survival,

#817 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Introduction: There are a few case reports on surgery after peptide receptor radionuclide therapy (PRRT).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bertani E, Chiappa A, Fazio N, Grana C, Bodei L,

Keywords: neuroendocrine tumors, peptide receptor radionuclide therapy, surgery, survival, progression-free survival,

#816 Resection at Diagnosis of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Liver Metastases. A Possible New Approach for a Multimodal Treatment

Introduction: Pancreatic neuroendocrine tumors (PNETs) present in more than 50% of cases with liver metastases as the only systemic localization. Liver metastases are unresectable in 80% of cases at diagnosis. In the context of metastatic disease, the benefit of primary tumor removal in terms of survival is controversial

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bertani E, Chiappa A, Fazio N, Falconi M, Spada F,

Keywords: pancreatic neuroendocrine tumor, synchronous liver metastases, debulking, resection, prognostic factors, survival,

#745 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) for Patients with Neuroendocrine Tumors (NETs) with Metastatic Abdominal Localizations.

Introduction: There are only few case reports about surgery in patients affected by gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients previously underwent peptide receptor radionuclide therapy (PRRT).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Bertani E

Authors: Bertani E, Fazio N, Cossu M, Chiappa A, Corbellini C,

Keywords: gastroenteropancreatic neuroendocrine tumors, surgery, peptide receptor radionuclide therapy, multidisciplinary approach, long-term survival.,